Human response to COVID-vaccination in MS

9th December 2021, Pre-MENACTRIMS symposium, as a warm-up for the Sixth MENACTRIMS Congress, ParadigMS Foundation organised this enriching Pre-MENACTRIMS Symposium. Here you can review the full keynote on Human response to COVID-vaccination in MS.

ABSTRACT

Most multiple sclerosis (MS) patients infected with COVID-19 had a mild-moderate infection, with no more relapses or more severe disease course than MS-free patients. This session shed light on the response to vaccination of MS patients, including the influence of the chosen MS treatment on vaccine response. Watch to hear more about the production of antibodies in vaccinated MS patients and the influence of the MS treatment on antibodies production.

CELIA OREJA-GUEVARA
Vice Chair of Neurology and Head of Multiple Sclerosis Center at University Hospital San Carlos, Madrid

Professor Celia Oreja-Guevara is Vice Chair of Neurology and Head of Multiple Sclerosis Center at the University Hospital San Carlos, Madrid and Professor of Neurology at the University Complutense, Madrid, Spain.
After receiving her MD from the University Complutense, Madrid, Professor Oreja-Guevara completed a PhD in neuroimmunology at the Max-Planck-Institute for Neurobiology, University of Munich, Munich (Germany). She then went on to complete a residency in the Department of Neurology at the University of Bochum, Bochum (Germany) and a postdoctoral fellowship in neuroimaging at the University Hospital San Raffaele, Milan (Italy). She has also held posts at the University of Düsseldorf (Germany),Hospital de Fuenlabrada and at the University Hospital La Paz, both in Madrid.

Professor Oreja-Guevara’s research interests centre on clinical and neuroimaging correlations in MS and the use of optical coherence tomography. Neuromyelitis optica (NMO) is among her other therapy areas of interest, and Professor Oreja-Guevara is actively involved in the evaluation of new drugs for the treatment of MS and NMO. As an investigator, she has participated in a number of MS clinical trials and currently heads the Neuroimaging Group of the Spanish Neurological Society, and she is a member of the Scientific Committee of the European Academy of Neurology. Currently, Professor Oreja-Guevara is an expert for the Spanish Medicines Agency and for the Scientific Advisory Group on Neurology of the European Medicines Agency.

We value your opinion.

How likely are you to recommend this material to a friend or colleague?

Selected Value: 1

Give a score from 1 (= not at all likely) to 10 (extremely likely)

Tell us what you think or ask a question to the expert.

Give your opinion on the quality of the material and send us your comments, questions or feedback. Where relevant, we'll liaise with the Expert and get back to you.

Email

If you have submitted a question above, leave your email so we can get back to you.

are think Email

Submit